Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allovir Inc (NQ: ALVR )

0.8065 -0.0035 (-0.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allovir Inc

< Previous 1 2 3 4 5 Next >
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
From AlloVir, Inc.
Via Business Wire
AlloVir to Participate in the SVB Securities Global Biopharma Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
From AlloVir, Inc.
Via Business Wire
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
From AlloVir
Via Business Wire
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
From AlloVir
Via Business Wire
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Third Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Second Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
AlloVir Announces $126.6 Million Registered Direct Offering
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
From AlloVir, Inc.
Via Business Wire
AlloVir Reports First Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
From AlloVir
Via Business Wire
AlloVir Appoints Shawn Tomasello to Its Board of Directors
From AlloVir
Via Business Wire
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
From AlloVir
Via Business Wire
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From AlloVir
Via Business Wire
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
From AlloVir
Via Business Wire
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
From AlloVir
Via Business Wire
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
From AlloVir
Via Business Wire
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
From AlloVir
Via Business Wire
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
From AlloVir
Via Business Wire
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Third Quarter 2021 Financial Results
From AlloVir
Via Business Wire
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
From AlloVir, Inc.
Via Business Wire
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
From AlloVir, Inc.
Via Business Wire
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Second Quarter 2021 Financial Results
From AlloVir
Via Business Wire
AlloVir Reports First Quarter 2021 Financial Results
From AlloVir
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.